Adding sintilimab to pemetrexed and platinum chemotherapy boosts PFS.
-
Sintilimab plus combination therapy yields good results in advanced NSCLC -
The seven antibody panel demonstrated high specificity and moderate sensitivity for detecting lung cancer at two years.
-
Lung cancer screening in high-risk people yields high rate of early-stage disease More than 70% of those diagnosed were stage I-II, and many could choose therapy with curative intent.
-
Lung cancer screening may be less harmful and more cost-effective than previously thought.
-
Concomitant NSCLC immunotherapy and beta blocker use offers PFS advantage Prior studies had suggested a benefit in other cancers.
-
Do antiseizure drugs influence the risk of smoking-related COPD and lung cancer? Findings from a UK population-based case-control study.
-
Enzyme-inducing antiseizure drugs lower lung cancer, COPD risk in smokers Association was strongest in light smokers and short- and moderate-term ASD users.
-
Should PORT be standard of care in pN2 NSCLC? Clinical trial results are pending, but meta-analysis finds OS benefit only in select patients.
-
CONUT score effective, easy-to-use predictor for PPCs after NSCLC surgery Patients with high controlling nutritional status score nearly twice as likely to develop a PPC.
-
NSCLC: VATS tops open lobectomy for short- and long-term OS Meta-analysis found lower mortality at 30 days and 3, 5, and 8 years.
-
Does percutaneous transthoracic needle biopsy increase lung cancer recurrence risk? Yes, but only pleural recurrence and only in those with subpleural lesions.
-
Findings emphasise the importance of promoting physical activity.
-
COVID-19-delayed cancer diagnoses predicted to increase cancer deaths Lung, breast, colorectal, esophageal cancer deaths are all expected to rise.
-
NSCLC: most patients with brain metastases have neurological symptoms at diagnosis But the number of asymptomatic patients has increased since 1986.